Drugs / SAR125844
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01657214 | Sep 2012 → Jan 2016 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01391533 | Jul 2011 → Apr 2016 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02435121 | Nov 2015 → Jan 2016 | cancer | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR125844 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01657214 ↗ |
| Action | Inhibit | “a highly selective MET kinase inhibitor (SAR125844)” PMID 29145039 ↗ Nov 2017 |
| Modality | Small molecule | — CHEMBL4461070 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT01391533 ↗ |
| Target | MET | “a highly selective MET kinase inhibitor (SAR125844)” PMID 29145039 ↗ Nov 2017 |